US FDA Trains Reviewers For Consistency On Post-Q12 Manufacturing Changes

Anticipating the eventual adoption of ICH Q12, the US FDA is training staff on some of its key principles. An agency official says ICH Q12 necessitates a new way of thinking about and reviewing regulatory submissions for post-approval changes and such training is necessary to ensure review consistency.

Business Team Training Listening Meeting Concept - Image
The FDA trains staff on ich q12 as guidance nears final approval • Source: Shutterstock

The US Food and Drug Administration has launched a training program for agency reviewers on some of the core concepts in the International Council for Harmonization’s draft Q12 guideline on pharmaceutical product lifecycle management. The draft guideline has prompted a new way of thinking about manufacturing changes, and the agency wants to ensure that reviewers are on the same page ahead of its eventual adoption, expected in November.

Kavita Vyas, a reviewer in the FDA’s Center for Drug Evaluation and Research, described the elements of the training at...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance